Cervical dystonia, a chronic neurological disorder causing involuntary muscle contractions in the neck, leading to abnormal head postures and significant discomfort. According to Kamlesh P. Kakde et al., 2025, the prevalence of cervical dystonia has increased from 0.0164% in 2023 to 0.03% in 2024 globally. The treatment landscape includes botulinum toxin injections, anticholinergics, and deep brain stimulation. According to the cervical dystonia pipeline analysis by Expert Market Research, the market is set for significant advancement in the coming years.
Major companies involved in the cervical dystonia pipeline analysis include Ipsen, Motric Bio, and others.
Leading drugs currently in the pipeline include MTR-601, IPN10200, and others.
The cervical dystonia drug pipeline is expanding due to rising R&D in botulinum toxin formulations, increased clinical trials of neuromodulators, and growing interest in gene-targeted therapies.
The Cervical Dystonia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into cervical dystonia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cervical dystonia. The cervical dystonia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cervical dystonia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cervical dystonia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cervical dystonia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cervical dystonia, also known as spasmodic torticollis, is a chronic neurological disorder that causes involuntary muscle contractions in the neck, leading to abnormal head postures and movements. It typically occurs due to improper brain signaling affecting muscle control, often developing in middle age without a clear cause.
Cervical dystonia treatment involves botulinum toxin injections, oral medications, or physical therapy to reduce muscle contractions. In severe cases, deep brain stimulation may be considered to manage persistent symptoms. In August 2023, the United States Food and Drug Administration approved Daxxify (daxibotulinumtoxinA-lanm) for cervical dystonia. This botulinum toxin demonstrated significant improvement in muscle control and symptom reduction in the ASPEN-1 trial.
According to Kamlesh P. Kakde et al., 2025, the global prevalence of cervical dystonia increased from 0.0164% in 2023 to 0.03% in 2024. In India, the 2023 prevalence rate was 0.0077% among individuals under 30 and 0.1779% in those aged 50–70 years. As per Harald Hefter et al., 2025, cervical dystonia affects around 100 per million in Europe, with rates ranging from 1:50,000 in Japan to 1:250 in some U.S. regions. The rising prevalence underscores the need for accelerated drug development and targeted therapeutic research.
This section of the report covers the analysis of cervical dystonia drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The cervical dystonia pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II accounts for 75%, covers a major share of the total cervical dystonia clinical trials. This reflects a strong focus on clinical development. Phase IV represents 25%, indicating the presence of post-marketing research. The robust activity in phase II highlights ongoing innovation, while phase IV ensures long-term safety monitoring. Together, these efforts can significantly strengthen treatment options in the cervical dystonia market.
The drug molecule categories covered under the cervical dystonia pipeline analysis include small molecules, biologics, gene therapies, peptides, and RNA-based therapies. The cervical dystonia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cervical dystonia. Botulinum toxin therapies remain the cornerstone in the drug class segment for managing cervical dystonia. DaxibotulinumtoxinA for injection (DAXI) is a novel, highly purified botulinum toxin type A formulation developed by Revance Therapeutics. It includes a proprietary stabilizing peptide, RTP004, designed to prolong therapeutic effects. In the ASPEN-1 Phase 3 trial, DAXI showed significant symptom reduction and extended efficacy lasting over 20 weeks, supporting its potential as a long-acting treatment option.
The EMR report for the Cervical Dystonia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cervical dystonia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cervical dystonia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cervical dystonia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cervical dystonia drug candidates.
MTR-601 is an investigational oral therapy sponsored by Motric Bio, currently under evaluation in a Phase 2a study for the treatment of cervical dystonia. This randomized, placebo-controlled trial is examining the safety, tolerability, and efficacy of MTR-601 over 8 weeks. MTR-601 is a novel, selective myosin-2 inhibitor that targets fast-twitch skeletal muscle fibers to reduce stiffness and improve motor function. The study has approximately 80 participants, aiming to offer a non-invasive alternative to botulinum toxin treatments. Participants are receiving daily capsules under double-blind conditions.
IPN10200 is being evaluated by Ipsen in a Phase II clinical trial for treating cervical dystonia (CD) in adults. The objective of this phase is to assess the efficacy and safety of IPN10200 compared to placebo. IPN10200 is a novel, modified recombinant botulinum neurotoxin serotype AB, designed for longer-lasting muscle relaxation. It targets abnormal neck and head muscle contractions by blocking nerve signals. The study is enrolling 132 participants and includes a 36-week treatment period followed by comprehensive clinical evaluations and monitoring.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Cervical Dystonia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cervical dystonia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cervical dystonia collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share